Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial Two new indications bring Daiichi Sankyo and AstraZeneca’s Enhertu into curative-intent setting, reinforcing its role across stages of HER2 positive breast cancer Enhertu now approved for nine indications with six across both early and metastatic … [Read more…]
